Haptoglobin polymorphism as a risk factor for coronary heart disease mortality

被引:60
作者
De Bacquer, D
De Backer, G
Langlois, M
Delanghe, J
Kesteloot, H
Kornitzer, M
机构
[1] Ghent Univ, Dept Publ Hlth, B-9000 Ghent, Belgium
[2] Ghent Univ, Dept Clin Chem, B-9000 Ghent, Belgium
[3] Univ Leuven, Dept Endocrinol, Louvain, Belgium
[4] Free Univ Brussels, Sch Publ Hlth, Brussels, Belgium
关键词
coronary heart disease; haptoglobin polymorphism; longitudinal;
D O I
10.1016/S0021-9150(00)00690-0
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives: the aim of our study was to evaluate the independent role of the haptoglobin (Hp) polymorphism as a risk factor for coronary heart disease (CHD) mortality. Methods: within the framework of the longitudinal part of the Belgian Interuniversity Research on Nutrition and Health (BIRNH) survey, a nested case-control study design was performed through matching the 107 deaths from CHD, occurring within a 10-year follow-up period, with three controls for age and gender. Results: the distribution of the Hp types was found to be in Hardy-Weinberg equilibrium. Conditional logistic regression analysis for matched sets revealed that the Hp polymorphism was significantly associated with CHD death. Rather surprisingly, the finding was that Hp 1-1 individuals were at doubled risk for CHD mortality compared with the others, the odds ratio being 2.09 (95% CI. 1.22-3.60). The association was independent from other classical cardiovascular risk factors and the Hp concentration, and of comparable magnitude between men and women. Moreover, evaluating the interaction term in a multiplicative model showed that the Hp type did not play a synergistic role in the prognostic value of established cardiovascular risk factors. Conclusion: in contrast to the findings from cross-sectionally based studies, the results from this longitudinal study show that Hp 1-1 individuals are at elevated risk for CHD mortality. (C) 2001 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:161 / 166
页数:6
相关论文
共 26 条
[1]  
Berkova N, 1999, J IMMUNOL, V162, P6226
[2]  
Blackburn H, 1969, J Electrocardiol, V2, P5, DOI 10.1016/S0022-0736(69)80044-0
[3]  
Breslow NE, 1980, ANAL CASE CONTROL ST, V1
[4]   EFFECT OF THE HAPTOGLOBIN PHENOTYPE ON THE SIZE OF A MYOCARDIAL INFARCT [J].
CHAPELLE, JP ;
ALBERT, A ;
SMEETS, JP ;
HEUSGHEM, C ;
KULBERTUS, HE .
NEW ENGLAND JOURNAL OF MEDICINE, 1982, 307 (08) :457-463
[5]   IDENTIFICATION OF HAPTOGLOBIN AS AN ANGIOGENIC FACTOR IN SERA FROM PATIENTS WITH SYSTEMIC VASCULITIS [J].
CID, MC ;
GRANT, DS ;
HOFFMAN, GS ;
AUERBACH, R ;
FAUCI, AS ;
KLEINMAN, HK .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 91 (03) :977-985
[6]  
Dati F, 1996, EUR J CLIN CHEM CLIN, V34, P517
[7]   Fast determination of haptoglobin phenotype and calculation of hemoglobin binding capacity using high pressure gel permeation chromatography [J].
Delanghe, J ;
Allcock, K ;
Langlois, M ;
Claeys, L ;
De Buyzere, M .
CLINICA CHIMICA ACTA, 2000, 291 (01) :43-51
[8]   Haptoglobin polymorphism, a genetic risk factor in coronary artery bypass surgery [J].
Delanghe, J ;
Cambier, B ;
Langlois, M ;
DeBuyzere, M ;
Neels, H ;
DeBacquer, D ;
VanCauwelaert, P .
ATHEROSCLEROSIS, 1997, 132 (02) :215-219
[9]   Haptoglobin polymorphism and peripheral arterial occlusive disease [J].
Delanghe, J ;
Langlois, M ;
Duprez, D ;
De Buyzere, M ;
Clement, D .
ATHEROSCLEROSIS, 1999, 145 (02) :287-292
[10]  
Delanghe J R, 1995, J Cardiovasc Risk, V2, P131, DOI 10.1097/00043798-199504000-00008